Pro-Dex Inc. reported net income of $4.7 million, or $1.40 per diluted share, for the quarter ended September 30, 2025, compared to $2.5 million, or $0.75 per diluted share, in the same period of the previous year. The net income for the most recent quarter includes unrealized gains on marketable equity investments of $3.3 million, compared to $433,000 in unrealized gains in the prior year's quarter. The company's investment in Monogram Technologies, Inc. was valued at the cash price received in October 2025 upon its acquisition by Zimmer Biomet Holdings, Inc., resulting in cash proceeds of $8.9 million. Operating income for the quarter increased by $0.1 million, or 3%, to $3.1 million, compared to $3.0 million in the previous year's corresponding period. Gross profit rose by $0.2 million, or 4%, while gross margin declined to 29% from 35% in the prior year, mainly due to higher costs including tariffs. Operating expenses rose by $0.1 million, or 6%, to $2.3 million, attributed primarily to increased personnel costs related to human resources, information technology, and facilities.